Targeting Inflammation in Acute Coronary Syndrome Using Colchicine

Colchicine Compared With Placebo to Reduce Hs-CRP in Patients With Acute Coronary Syndromes- Targeting Inflammation in Atherosclerosis Trial

The purpose of this study is to evaluate the effect of colchicine on high sensitivity C-reactive protein (hs-CRP), a blood marker to measure inflammation, in patients with acute coronary syndromes.

Inclusion Criteria:

• All patients with a diagnosis of acute coronary syndrome who are > 18 years old and who do not have any contraindication to colchicine.

Exclusion Criteria:

• Contraindication to colchicine including any of the following:

  • hypersensitivity to colchicine
  • severe renal, hepatic or gastrointestinal disorder
  • blood dyscrasias (myelodysplasia cytopenias etc)

• Concurrent use of moderate-strong CYP3A4 inhibitors (a complete list is appended in the full protocol)

• Known severe liver disease and/or elevated transaminases > 1.5x the upper limit of normal

• Estimated GFR < 50 ml/min

• Pregnant or lactating women or women not protected by a reliable contraception method

• Current treatment with colchicine at enrollment

• Active infection or systemic inflammation eg active rheumatoid arthritis